Results 1 to 10 of about 447 (114)

Efficacy and safety of levosimendan in patients with sepsis: a systematic review and network meta-analysis [PDF]

Frontiers in Pharmacology
Objective: We conducted a systematic review to assess the advantages and disadvantages of levosimendan in patients with sepsis compared with placebo, milrinone, and dobutamine and to explore the clinical efficacy of different concentrations of ...
Ruimin Tan, Ruimin Tan, He Guo, He Guo, Zinan Yang, Zinan Yang, Huihui Yang, Huihui Yang, Qinghao Li, Qinghao Li, Qiong Zhu, Quansheng Du   +11 more
doaj   +2 more sources

Levosimendán preoperatorio en cirugía coronaria con disfunción ventricular severa: ¿tiene sentido?

Cirugía Cardiovascular, 2021
Resumen: Introducción y objetivos: Numerosos estudios han demostrado los beneficios del levosimendán en pacientes con insuficiencia cardiaca crónica y aguda; sin embargo, los resultados son contradictorios cuando se analiza el uso de levosimendán previo
Elena Roselló-Díez, Eduardo Astrosa, Sandra Casellas, Manel Tauron, Josefina Galán, Antonino Ginel, José Montiel   +6 more
doaj   +1 more source

The effect of post-reperfusion levosimendan in an experimental intestinal ischemia–reperfusion model

Journal of Anesthesia, Analgesia and Critical Care, 2022
Background Levosimendan has been reported to have a positive effect on ischemia–reperfusion injury. Herein, we aimed to evaluate the effects of levosimendan applied after reperfusion in an experimental intestinal injury-reperfusion (IR) model.
Hakan Aygun, Cimen Olguner, Ugur Koca, Bekir Ugur Ergur, Ali Rıza Sisman, Duyguhan Isguven, Pelin Girgin, Muhammed Akkus, Serkan Tulgar   +8 more
doaj   +1 more source

Levosimendan Efficacy and Safety: 20 Years of SIMDAX in Clinical Use [PDF]

, 2020
Levosimendan was first approved for clinical use in 2000, when authorization was granted by Swedish regulatory authorities for the hemodynamic stabilization of patients with acutely decompensated chronic heart failure (HF).
Agostoni P., Alvarez J., Bettex D., Bouchez S., Brito D., Cerny V., Comin-Colet J., Crespo-Leiro M. G., Delgado J. F., Edes I., Eremenko A. A., Farmakis D., Fedele F., Fonseca C., Fruhwald S., Girardis M., Guarracino F., Harjola V. -P., Heringlake M., Herpain A., Heunks L. M. A., Husebye T., Ivancan V., Karason K., Kaul S., Kivikko M., Kubica J., Lewinski D. V., Masip J., Matskeplishvili S., Mebazaa A., Nieminen M. S., Oliva F., Papp J. G., Papp Z., Parissis J., Parkhomenko A., Poder P., Pollesello P., Polzl G., Reinecke A., Ricksten S. -E., Riha H., Rudiger A., Sarapohja T., Schwinger R. H. G., Toller W., Tritapepe L., Tschope C., Vrtovec B., Wikstrom G.   +50 more
core   +15 more sources

Levosimendan increases the phosphorylation state of phospholamban in the isolated human atrium [PDF]

, 2023
Levosimendan (up to 10 µM) given alone failed to increase force of contraction in isolated electrically stimulated (1 Hz) left atrial (LA) preparations from wild-type mice.
Abella, Lina Maria Rayo, Gergs, Ulrich, Hoffmann, Robert, Hofmann, Britt, Neumann, Joachim   +4 more
core   +1 more source

Vasoactive agents in acute mesenteric ischaemia in critical care. A systematic review [PDF]

, 2021
Acknowledgements With thanks to Helen Fulbright, PhD, MA, PGDip LIS, BA (Hons), MCLIP, Information Specialist, Royal College of Surgeons of England Library and Archives Team, for conducting the literature searchesPeer reviewedPublisher ...
Brennan, Christopher A., Forget, Patrice, Kaye, Callum, McClenaghan, Rachael Eimear, Nassar, Ahmed, Osei-Bonsu, Peter, Ramsay, George   +6 more
core   +2 more sources

Levosimendan for the prevention of acute organ dysfunction in sepsis [PDF]

, 2016
BACKGROUND Levosimendan is a calcium-sensitizing drug with inotropic and other properties that may improve outcomes in patients with sepsis. METHODS We conducted a double-blind, randomized clinical trial to investigate whether levosimendan reduces the ...
Al-Beidh, F, Ashby, D, Best-Lane, J, Brealey, D, Breen, A, Cross, M, Gordon, AC, Liu, KD, Mason, AJ, McAuley, DF, McNamee, JJ, Nutt, CL, Orme, RML, Perkins, GD, Reschreiter, H, Santhakumaran, S, Singer, M   +16 more
core   +2 more sources

Levosimendan: current data, clinical use and future development. [PDF]

, 2013
Levosimendan is an inodilator indicated for the short-term treatment of acutely decompensated severe chronic heart failure, and in situations where conventional therapy is not considered adequate. The principal pharmacological effects of levosimendan are
Fruhwald, S, Gordon, AC, Heunks, LM, Kivikko, M, Nieminen, MS, Pollesello, P, Suominen, PK   +6 more
core   +6 more sources

Levosimendan in critical illness: A literature review [PDF]

, 2014
Levosimendan, the active enantiomer of simendan, is a calcium sensitizer developed for treatment of decompensated heart failure, exerts its effects independently of the beta adrenergic receptor and seems beneficial in cases of severe, intractable heart ...
Franchi, Federico, Karanikolas, Menelaos, Muzzi, Luigi, Pierrakos, Charalampos, Scolletta, Sabino, Velissaris, Dimitrios   +5 more
core   +2 more sources

Levosimendan protects against ischemia – reperfusion injury in the human heart muscle. A pilot study [PDF]

, 2022
The consequences of myocardial infarction (MI) are an increasing problem worldwide. Despite spectacular progress in the invasive treatment of ischemic heart disease, the ability to limit the ischemia-reperfusion (I/R) injury remains largely unrealized ...
Biernat, Jolanta, Biernat, Jolanta, Deja, Marek Andrzej, Deja, Marek Andrzej, Golba, Krzysztof Stanislaw, Golba, Krzysztof Stanislaw, Kunecki, Marcin, Kunecki, Marcin, Nozynski, Jerzy, Nozynski, Jerzy, Oleksy, Tomasz, Oleksy, Tomasz, Plazak, Wojciech, Plazak, Wojciech, Podolec, Piotr, Podolec, Piotr   +15 more
core   +2 more sources